Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Cloudbreak Therapeutics logo — Leading the future of eye care with efficient drug repurposi...

Cloudbreak Therapeutics

Leading the future of eye care with efficient drug repurposing and fast-tracked clinical advancements.

Founded 2015 11-50 employees Series C Total: $171.22M Biotechnology, Health Care

General Information

Company Name Cloudbreak Therapeutics
Founded Year 2015
Employees 11-50
Industries Biotechnology, Health Care
Funding Stage Series C
Social

Get notified when Cloudbreak Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cloudbreak Therapeutics

Cloudbreak Therapeutics is a clinical-stage biotechnology company pioneering the future of eye care through efficient drug repurposing and fast-tracked clinical advancements. Established in 2015, the company focuses on ocular drug development, employing a capital-efficient business model based on VIC + 505b(2). This approach involves repurposing approved systemic drugs for ocular delivery to effectively treat various eye diseases. The company’s strategy enables the rapid advancement of drug candidates, moving swiftly through proof-of-concept (POC) Phase II clinical trials. Subsequently, they out-license global rights for Phase III clinical trials, product registration, and commercialization. Cloudbreak Therapeutics is fully engaged in the pharmaceutical development ecosystem, optimizing capital for drug development by partnering with contract research organizations (CRO) for non-clinical, CMC, and clinical development. In a significant milestone, Cloudbreak Therapeutics secured a substantial $130.00M Series C investment on January 1, 2022. The investment consortium included prominent firms such as EFung Capital, CDH Investments, CCB International, Dyee Capital, Grand Pharma, Industrial Securities Capital, CDF-Capital, Yuejun Investment, Yingke Capital, and ShenZhen GTJA Investment Group. This strategic investment underscores the confidence and support from leading investors in the company's innovative approach and its potential to revolutionize eye care. With a clear focus on biotechnology and healthcare industries, Cloudbreak Therapeutics stands poised to drive significant advancements in ocular drug development and positively impact the future of eye care.

Taxonomy: ocular drug development, clinical-stage company, drug repurposing, efficient capital model, VIC + 505b(2), proof-of-concept trials, contract research organizations, pharmaceutical development, CMC, out-licensing, global rights, commercialization, eye care, systemic drugs

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 10
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Jan 2022
Series B •••••• - 17 Apr 2020
Series A •••••• - 26 Oct 2018

Cloudbreak Therapeutics Alternatives & Competitors

Cloudbreak Therapeutics vs
TransPharma Medical
TransPharma Medical

Pioneering transdermal drug delivery to enhance therapeutic outcomes for osteoporosis and other pept...

Series C
Biotechnology, Health Care
Cloudbreak Therapeutics vs
hVIVO
hVIVO United Kingdom

A rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human ch...

Series B
248 employees
Biotechnology, Health Care
Cloudbreak Therapeutics vs
Treat U
Treat U

Innovative nanotechnology platforms for precise drug delivery, bringing significant value to patient...

Seed
Biotechnology, Health and Wellness

FAQ About Cloudbreak Therapeutics

Leading the future of eye care with efficient drug repurposing and fast-tracked clinical advancements.
Cloudbreak Therapeutics was founded in 2015.
Cloudbreak Therapeutics operates in the following industries: Biotechnology, Health Care.
Cloudbreak Therapeutics has approximately 11-50 employees.
Cloudbreak Therapeutics has completed 3 funding rounds, raising a total of $171.22M. The latest funding stage is Series C.
Top alternatives and competitors to Cloudbreak Therapeutics include TransPharma Medical, hVIVO, Treat U, MindBio Therapeutics, Ocular Therapeutix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cloudbreak Therapeutics and TransPharma Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cloudbreak Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy